SBRT and extreme hypofractionation: A new era in prostate cancer treatments?

Alongi, Filippo; Fiorentino, Alba; Bari, Berardino De

doi:10.1016/j.rpor.2014.09.005

Cited by 15 publications

(15 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, several studies have reported the efficacy of moderate hypofractionated RT for patients with prostate cancer [42][43][44][45]. Moreover, the clinical outcomes of extreme hypofractionated RT for those with prostate cancer have been recently reported [46][47][48]. According to these features of prostate cancer and because of the biological and physical advantages in CIRT, it is considered that CIRT is appropriate for the management of prostate cancer.…”

Section: Discussionmentioning

confidence: 99%

Preliminary result of carbon-ion radiotherapy using the spot scanning method for prostate cancer

et al. 2020

View full text Add to dashboard Cite

Background: Carbon-ion radiotherapy (CIRT) for prostate cancer was initiated at Kanagawa Cancer Center in 2015. The present study analyzed the preliminary clinical outcomes of CIRT for prostate cancer. Methods: The clinical outcomes of 253 patients with prostate cancer who were treated with CIRT delivered using the spot scanning method between December 2015 and December 2017 were retrospectively analyzed. The irradiation dose was set at 51.6 Gy (relative biological effectiveness) delivered in 12 fractions over 3 weeks. Biochemical relapse was defined using the Phoenix definition. Toxicities were assessed according to CTCAE version 4.0. Results: The median patient age was 70 (47-86) years. The median follow-up duration was 35.3 (4.1-52.9) months. According to the D'Amico classification system, 8, 88, and 157 patients were classified as having low, intermediate, and high risks, respectively. Androgen deprivation therapy was administered in 244 patients. The biochemical relapse-free rate in the low-, intermediate-, and high-risk groups at 3 years was 87.5, 88.0, and 97.5%, respectively (P = 0.036). Grade 2 acute urinary toxicity was observed in 12 (4.7%) patients. Grade 2 acute rectal toxicity was not observed. Grade 2 late urinary toxicity and grade 2 late rectal toxicity were observed in 17 (6.7%) and 3 patients (1.2%), respectively. Previous transurethral resection of the prostate was significantly associated with late grade 2 toxicity in univariate analysis. The predictive factor for late rectal toxicity was not detected. Conclusion: The present study demonstrated that CIRT using the spot scanning method for prostate cancer produces favorable outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Preliminary result of carbon-ion radiotherapy using the spot scanning method for prostate cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In fact, several studies have reported the e cacy of moderate hypofractionated RT for patients with prostate cancer [42][43][44][45]. Moreover, the clinical outcomes of extreme hypofractionated RT for those with prostate cancer have been recently reported [46][47][48]. According to these features of prostate cancer and because of the biological and physical advantages in CIRT, it is considered that CIRT is appropriate for the management of prostate cancer.…”

Section: Discussionmentioning

confidence: 99%

Preliminary result of carbon-ion radiotherapy using the spot scanning method for prostate cancer

Takakusagi

Kato²,

Kano

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Carbon-ion radiotherapy (CIRT) for prostate cancer was initiated at Kanagawa Cancer Center in 2015. The present study analyzed the preliminary clinical outcomes of CIRT for prostate cancer. Methods: The clinical outcomes of 253 patients with prostate cancer who were treated with CIRT delivered using the spot scanning method between December 2015 and December 2017 were retrospectively analyzed. The irradiation dose was set at 51.6 Gy (relative biological effectiveness) delivered in 12 fractions over 3 weeks. Biochemical relapse was defined using the Phoenix definition. Toxicities were assessed according to CTCAE version 4.0. Results: The median patient age was 70 (47–86) years. The median follow-up duration was 35.3 (4.1–52.9) months. According to the D’Amico classification system, 8, 88, and 157 patients were classified as having low, intermediate, and high risks, respectively. Androgen deprivation therapy was administered in 244 patients. The biochemical relapse-free rate in the low-, intermediate-, and high-risk groups at 3 years was 87.5%, 88.0%, and 97.5%, respectively (P = 0.036). Grade 2 acute urinary toxicity was observed in 12 (4.7%) patients. Grade 2 acute rectal toxicity was not observed. Grade 2 late urinary toxicity and grade 2 late rectal toxicity were observed in 17 (6.7%) and 3 patients (1.2%), respectively. Previous transurethral resection of the prostate was significantly associated with late grade 2 toxicity in univariate analysis. The predictive factor for late rectal toxicity was not detected.Conclusion: The present study demonstrated that CIRT using the spot scanning method for prostate cancer produces favorable outcomes.

show abstract

“…It uses nonuniform radiation beams to achieve tightly conformal dose distributions and ultra-high doses of over 80 Gy can be safely delivered [4,5]. This is especially relevant in light of the combination of IGRT and IMRT/ volumetric modulated arc radiotherapy in the context of stereotactic body radiation therapy/ stereotactic ablative radiotherapy (SBRT/SABR) treatments allowing delivery of higher total biological equivalent doses and/or higher dose per fraction [6]. However, in order for IMRT to be effective in reducing toxicity while increasing the target dosedespecially in regard to the adjacent membranous urethra, which remains at risk for urethral strictures with dose escalationdit is essential to localise the prostate or target volume accurately.…”

Section: Intensity-modulated Radiotherapymentioning

confidence: 99%

“…SIMAT was developed in order to improve dose conformity to the target volume and allow for dose escalation to the target volume [20]. There have been a substantial number of reports confirming that dose escalation results in improvement in biochemical relapse rates [6,7]. The delivery of SIMAT, as with any dose conforming method of treatment to the prostate, requires precise localisation of the prostate apex.…”

Section: Appendixmentioning

confidence: 99%

The Utility of Penile Bulb Contouring to Localise the Prostate Apex as Compared to Urethrography

Lock

Heinrichs

Bhattacharya

et al. 2018

Journal of Medical Imaging and Radiation Sciences

View full text Add to dashboard Cite

SBRT and extreme hypofractionation: A new era in prostate cancer treatments?

Abstract: Background: Considering that PC could have a low ␣/␤ ratio, similar to late-reacting normal

Cited by 15 publications

References 65 publications

Preliminary result of carbon-ion radiotherapy using the spot scanning method for prostate cancer

Preliminary result of carbon-ion radiotherapy using the spot scanning method for prostate cancer

Preliminary result of carbon-ion radiotherapy using the spot scanning method for prostate cancer

The Utility of Penile Bulb Contouring to Localise the Prostate Apex as Compared to Urethrography

Contact Info

Product

Resources

About